{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:59:43Z","timestamp":1792403983791,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T00:00:00Z","timestamp":1613260800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T00:00:00Z","timestamp":1613260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Lipoprotein-associated Phospholipase A2 (Lp-PLA2), can exert proinflammatory as well as proatherogenic properties on the vascular wall. The current study sought to evaluate the influence of high Lp-PLA2 levels on indices of arterial wall properties in patients with stable coronary artery disease (CAD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Three hundred seventy-four consecutive patients with stable CAD (mean age 61\u2009\u00b1\u200911\u2009years, 89% males) were enrolled in this single-center cross-sectional study. Flow-mediated dilation (FMD) was used to assess endothelial function and augmentation index (AIx) of the central aortic pressure was used to assess reflected waves. ELISA was used to determine Lp-PLA2 serum levels.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After dividing the participants in 3 equal groups based on the tertiles of circulating Lp-PLA2 values, no significant differences were demonstrated between those in the 3rd tertile with Lp-PLA2 values &gt;\u2009138\u2009\u03bcg\/L, in the 2nd tertile with Lp-PLA2 values between 101 and 138\u2009\u03bcg\/L and in the 1st tertile (Lp-PLA2 values &lt;\u2009101\u2009\u03bcg\/L) regarding age, male gender, smoking habits, family history of CAD or history of a previous myocardial infarction, diabetes mellitus, arterial hypertension, hyperlipidemia, duration of CAD and treatment with relevant medication. Importantly, subjects with Lp-PLA2 values in the highest tertile, had significantly reduced FMD values compared to the middle and lower tertile (4.43\u2009\u00b1\u20092.37% vs. 4.61\u2009\u00b1\u20091.97% vs. 5.20\u2009\u00b1\u20092.52% respectively, <jats:italic>P\u2009=<\/jats:italic>\u00a00.03). Patients in the highest tertile of Lp-PLA2 values had significantly higher AIx values (24.65\u2009\u00b1\u20098.69% vs. 23.33\u2009\u00b1\u20099.65%, <jats:italic>P\u2009=<\/jats:italic>\u00a00.03), in comparison\u00a0to the lowest tertile, with Lp-PLA2 values &lt;\u2009101\u2009\u03bcg\/L. A linear regression analysis showed that Lp-PLA2 values &gt;\u2009138\u2009\u03bcg\/L negatively correlated to FMD [b\u2009=\u2009\u2212\u20090.45 (95% CI: \u2212\u20090.79 \u2013 -0.11), <jats:italic>P\u2009=<\/jats:italic>\u00a00.01] and AIx values [b\u2009=\u20091.81 (95% CI: 0.57\u20133.05), <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001] independently of cofounders like gender, age, diabetes mellitus, arterial hypertension, dyslipidemia, smoking habits, family history of CAD, history of previous myocardial infarction, serum glucose, circulating lipid levels, duration of CAD, antihypertensive medication, antidiabetic drugs, statin therapy and treatment with \u03b2-blockers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Elevated Lp-PLA2 levels relate to endothelial dysfunction and arterial stiffness in patients with stable CAD independently from classical risk factors for CAD, statin use, antihypertensive treatment, and duration of the disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12944-021-01438-4","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:06:42Z","timestamp":1613347602000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8702-7369","authenticated-orcid":false,"given":"Konstantinos","family":"Mourouzis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Siasos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Oikonomou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Zaromitidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Tsigkou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Antonopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanthia","family":"Bletsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Stampouloglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Vlasis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manolis","family":"Vavuranakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris","family":"Tousoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,14]]},"reference":[{"key":"1438_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.atherosclerosis.2018.01.012","volume":"269","author":"F Gragnano","year":"2018","unstructured":"Gragnano F, Calabro P. Role of dual lipid-lowering therapy in coronary atherosclerosis regression: evidence from recent studies. Atherosclerosis. 2018;269:219\u201328.","journal-title":"Atherosclerosis."},{"key":"1438_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/1573403X15666190531111932","volume":"16","author":"A Santoso","year":"2019","unstructured":"Santoso A, Heriansyah T, Rochman S. Phospholipase a 2 is an inflammatory predictor in cardiovascular diseases: is there any spacious room to prove the causation? Curr Cardiol Rev. 2019;16:3\u201310.","journal-title":"Curr Cardiol Rev"},{"key":"1438_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/JAHA.116.003407","volume":"5","author":"L Wallentin","year":"2016","unstructured":"Wallentin L, Held C, Armstrong PW, Cannon CP, Davies RY, Granger CB, et al. Lipoprotein-associated phospholipase A2 activity is a marker of risk but not a useful target for treatment in patients with stable coronary heart disease. J Am Heart Assoc. 2016;5:1\u201316.","journal-title":"J Am Heart Assoc"},{"key":"1438_CR4","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1056\/NEJMoa1315878","volume":"370","author":"HD White","year":"2014","unstructured":"STABILITY Investigators, White HD, Held C, Stewart R, Tarka E, Brown R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014;370:1702\u201311.","journal-title":"N Engl J Med"},{"key":"1438_CR5","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/jama.2014.11061","volume":"312","author":"ML O\u2019Donoghue","year":"2014","unstructured":"O\u2019Donoghue ML, Braunwald E, White HD, Lukas MA, Tarka E, Steg PG, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA. 2014;312:1006\u201315.","journal-title":"JAMA."},{"key":"1438_CR6","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/MCA.0000000000000178","volume":"25","author":"Y Matsuzawa","year":"2014","unstructured":"Matsuzawa Y, Lerman A. Endothelial dysfunction and coronary artery disease: assessment, prognosis, and treatment. Coron Artery Dis. 2014;25:713\u201324.","journal-title":"Coron Artery Dis"},{"key":"1438_CR7","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.2174\/0929867326666190830103219","volume":"27","author":"E Oikonomou","year":"2020","unstructured":"Oikonomou E, Siasos G, Tsigkou V, Bletsa E, Panoilia ME, Oikonomou IN, et al. Coronary artery disease and endothelial dysfunction: novel diagnostic and therapeutic approaches. Curr Med Chem. 2020;27:1052\u201380.","journal-title":"Curr Med Chem"},{"key":"1438_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/978-3-319-77932-4_19","volume":"1065","author":"JK Li","year":"2018","unstructured":"Li JK. Arterial Wall properties in men and women: hemodynamic analysis and clinical implications. Adv Exp Med Biol. 2018;1065:291\u2013306.","journal-title":"Adv Exp Med Biol"},{"key":"1438_CR9","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1097\/HCO.0000000000000179","volume":"30","author":"I Ikonomidis","year":"2015","unstructured":"Ikonomidis I, Makavos G, Lekakis J. Arterial stiffness and coronary artery disease. Curr Opin Cardiol. 2015;30:422\u201331.","journal-title":"Curr Opin Cardiol"},{"key":"1438_CR10","first-page":"54011","volume":"110","author":"P Rodriguez-Miguelez","year":"2016","unstructured":"Rodriguez-Miguelez P, Seigler N, Harris RA. Ultrasound assessment of endothelial function: a technical guideline of the flow-mediated dilation test. J Vis Exp. 2016;110:54011.","journal-title":"J Vis Exp"},{"issue":"Pt 1","key":"1438_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/j.1469-7793.2000.t01-1-00263.x","volume":"525","author":"IB Wilkinson","year":"2000","unstructured":"Wilkinson IB, MacCallum H, Flint L, Cockcroft JR, Newby DE, Webb DJ. The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol. 2000;525(Pt 1):263\u201370.","journal-title":"J Physiol"},{"key":"1438_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12944-018-0800-y","volume":"17","author":"C Chi","year":"2018","unstructured":"Chi C, Teliewubai J, Lu YY, Fan XM, Yu SK, Xiong J, et al. Comparison of various lipid parameters in association of target organ damage: a cohort study. Lipids Health Dis. 2018;17:199.","journal-title":"Lipids Health Dis"},{"key":"1438_CR13","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1161\/HYPERTENSIONAHA.107.105668","volume":"51","author":"R Schnabel","year":"2008","unstructured":"Schnabel R, Larson MG, Dupuis J, Lunetta KL, Lipinska I, Meigs JB, et al. Relations of inflammatory biomarkers and common genetic variants with arterial stiffness and wave reflection. Hypertension. 2008;51:1651\u20137.","journal-title":"Hypertension."},{"key":"1438_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.atherosclerosis.2014.02.004","volume":"234","author":"I Ikonomidis","year":"2014","unstructured":"Ikonomidis I, Kadoglou NN, Tritakis V, Paraskevaidis I, Dimas K, Trivilou P, et al. Association of Lp-PLA2 with digital reactive hyperemia, coronary flow reserve, carotid atherosclerosis and arterial stiffness in coronary artery disease. Atherosclerosis. 2014;234:34\u201341.","journal-title":"Atherosclerosis."},{"key":"1438_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.atherosclerosis.2017.01.006","volume":"257","author":"M Kim","year":"2017","unstructured":"Kim M, Yoo HJ, Kim M, Ahn HY, Park J, Lee SH, et al. Associations among oxidative stress, Lp-PLA2 activity and arterial stiffness according to blood pressure status at a 3.5-year follow-up in subjects with prehypertension. Atherosclerosis. 2017;257:179\u201385.","journal-title":"Atherosclerosis."},{"key":"1438_CR16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4330\/wjc.v8.i2.231","volume":"8","author":"V Tritakis","year":"2016","unstructured":"Tritakis V, Tzortzis S, Ikonomidis I, Dima K, Pavlidis G, Trivilou P, et al. Association of arterial stiffness with coronary flow reserve in revascularized coronary artery disease patients. World J Cardiol. 2016;8:231\u20139.","journal-title":"World J Cardiol"},{"key":"1438_CR17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ijcard.2012.09.210","volume":"165","author":"D Tousoulis","year":"2013","unstructured":"Tousoulis D, Papageorgiou N, Androulakis E, Stefanadis C. Lp-PLA2--a novel marker of atherosclerosis: to treat or not to treat? Int J Cardiol. 2013;165:213\u20136.","journal-title":"Int J Cardiol"},{"key":"1438_CR18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1161\/01.ATV.0000191655.87296.ab","volume":"26","author":"EH Yang","year":"2006","unstructured":"Yang EH, McConnell JP, Lennon RJ, Barsness GW, Pumper G, Hartman SJ, et al. Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol. 2006;26:106\u201311.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1438_CR19","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1161\/CIRCULATIONAHA.106.671420","volume":"115","author":"S Lavi","year":"2007","unstructured":"Lavi S, McConnell JP, Rihal CS, Prasad A, Mathew V, Lerman LO, et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation. 2007;115:2715\u201321.","journal-title":"Circulation."},{"key":"1438_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1472-8206.2011.01023.x","volume":"26","author":"F Zannad","year":"2012","unstructured":"Zannad F, De Backer G, Graham I, Lorenz M, Mancia G, Morrow DA, et al. Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques. Fundam Clin Pharmacol. 2012;26:163\u201374.","journal-title":"Fundam Clin Pharmacol"},{"key":"1438_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP171764.APPGL","volume":"23","author":"PS Jellinger","year":"2017","unstructured":"Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. American Association of Clinical Endocrinologists and American College of endocrinology guidelines for Management of Dyslipidemia and Prevention of cardiovascular disease. Endocr Pract. 2017;23:1\u201387.","journal-title":"Endocr Pract"},{"key":"1438_CR22","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.jacc.2007.11.079","volume":"51","author":"ER Mohler 3rd","year":"2008","unstructured":"Mohler ER 3rd, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2008;51:1632\u201341.","journal-title":"J Am Coll Cardiol"},{"key":"1438_CR23","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1161\/CIRCULATIONAHA.105.612630","volume":"113","author":"M O'Donoghue","year":"2006","unstructured":"O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin or atorVastatin evaluation and infection therapy-thrombolysis in myocardial infarction) trial. Circulation. 2006;113:1745\u201352.","journal-title":"Circulation."},{"key":"1438_CR24","doi-asserted-by":"publisher","first-page":"e005077","DOI":"10.1161\/JAHA.116.005077","volume":"6","author":"C Held","year":"2017","unstructured":"Held C, White HD, Stewart RAH, Budaj A, Cannon CP, Hochman JS, et al. Inflammatory biomarkers Interleukin-6 and C-reactive protein and outcomes in stable coronary heart disease: experiences from the STABILITY (stabilization of atherosclerotic plaque by initiation of Darapladib therapy) trial. J Am Heart Assoc. 2017;6:e005077.","journal-title":"J Am Heart Assoc"},{"key":"1438_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ahj.2008.08.010","volume":"157","author":"A Sachdeva","year":"2009","unstructured":"Sachdeva A, Cannon CP, Deedwania PC, Labresh KA, Smith SC Jr, Dai D, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in get with the guidelines. Am Heart J. 2009;157:111\u20137.","journal-title":"Am Heart J"},{"key":"1438_CR26","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.2337\/db06-1573","volume":"56","author":"JP Corsetti","year":"2007","unstructured":"Corsetti JP, Ryan D, Moss AJ, Rainwater DL, Zareba W, Sparks CE. Glycoprotein Ibalpha polymorphism T145M, elevated lipoprotein-associated phospholipase A2, and hypertriglyceridemia predict risk for recurrent coronary events in diabetic postinfarction patients. Diabetes. 2007;56:1429\u201335.","journal-title":"Diabetes."},{"key":"1438_CR27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1055\/s-0037-1605564","volume":"44","author":"P Calabro","year":"2018","unstructured":"Calabro P, Gragnano F, Golia E, Grove EL. von Willebrand factor and venous thromboembolism: pathogenic link and therapeutic implications. Semin Thromb Hemost. 2018;44:249\u201360.","journal-title":"Semin Thromb Hemost"},{"key":"1438_CR28","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2174\/1570161115666170201114835","volume":"15","author":"F Gragnano","year":"2017","unstructured":"Gragnano F, Golia E, Natale F, Bianchi R, Pariggiano I, Crisci M, et al. Von Willebrand factor and cardiovascular disease: from a biochemical marker to an attractive therapeutic target. Curr Vasc Pharmacol. 2017;15:404\u201315.","journal-title":"Curr Vasc Pharmacol"},{"key":"1438_CR29","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/1479164116683149","volume":"14","author":"NK Acharya","year":"2017","unstructured":"Acharya NK, Qi X, Goldwaser EL, Godsey GA, Wu H, Kosciuk MC, et al. Retinal pathology is associated with increased blood-retina barrier permeability in a diabetic and hypercholesterolaemic pig model: beneficial effects of the LpPLA2 inhibitor Darapladib. Diab Vasc Dis Res. 2017;14:200\u201313.","journal-title":"Diab Vasc Dis Res"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01438-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12944-021-01438-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01438-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:09:01Z","timestamp":1613347741000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-021-01438-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,14]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1438"],"URL":"https:\/\/doi.org\/10.1186\/s12944-021-01438-4","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,14]]},"assertion":[{"value":"13 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants signed written informed consent. The study conforms to the ethical guidelines of the Declaration of Helsinki. The study protocol was a priori approved by the ethics committee of the Hippokration General Hospital of Athens (Ethics Committee Approval Number: 15\/10-2-2011). All participants were appropriately informed and gave written consent before entering the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to publish the present results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}